Integrated vortex-assisted electroporation platform with enhanced throughput for genetic delivery to primary cells

This paper presents an integrated vortex-assisted electroporation platform that overcomes the limitations of conventional bulk systems by combining size-selective cell trapping with optimized electrical and buffer conditions to achieve high-throughput, uniform genetic delivery of plasmid DNA and mRNA into heterogeneous primary human cells.

The Gist

Imagine you are a master chef trying to cook a very delicate, rare ingredient: primary human cells. These are cells taken directly from a person's body (like a skin or blood sample). They are the "gold standard" for medical research because they act exactly like the cells in a real human, unlike lab-grown "zombie" cells that have been modified to live forever.

The problem? These delicate cells are incredibly hard to cook with. To study them, scientists need to inject them with new genetic instructions (like DNA or mRNA), but these cells are shy, fragile, and come in all different sizes. Traditional methods are like trying to force a square peg into a round hole: they either kill the cells or fail to get the instructions inside.

This paper introduces a new, high-tech kitchen tool called the Vortex-Assisted Electroporation Platform. Here is how it works, explained through simple analogies:

1. The "Whirlpool Sorter" (Vortex Trapping)

Imagine a busy highway where cars of all sizes are driving. You only want to catch the big trucks, but you don't want to stop the whole traffic.

• The Old Way: You try to grab every car, but you miss the trucks or catch too many small cars.
• The New Way: The device creates tiny, controlled whirlpools (vortices) in a micro-channel. Think of these whirlpools like a gentle whirlpool in a bathtub.
  • Small, light objects (like dust or tiny cells) just spin around and wash away.
  • Big, heavy objects (the specific primary cells you want) get caught in the center of the whirlpool and held in place.
  • The Result: The machine automatically sorts the cells by size, trapping only the ones that are big enough to be useful, while letting the rest flow past.

2. The "Electric Shock Absorber" (Electroporation)

Once the cells are caught in the whirlpools, they need to be "opened up" so the genetic instructions can get inside.

• The Analogy: Imagine the cell is a locked house. To get inside, you need to briefly knock a hole in the wall.
• The Tool: The machine uses a precise electric pulse (like a tiny, controlled lightning bolt) to punch a temporary hole in the cell's wall.
• The Innovation: In the past, these electric shocks were like using a sledgehammer on a delicate watch. They were too strong, too uneven, or killed the cells.
  • This new platform redesigned the "wiring" (the electrode array) to be like a high-efficiency power grid. Instead of one long, weak wire, they created a grid of 144 tiny, parallel power stations.
  • This ensures every single cell gets the exact same amount of electric "tap" to open the door, without frying the house.

3. The "High-Speed Assembly Line" (Throughput)

The biggest breakthrough is speed.

• The Old Way: Previous machines were like a slow, manual assembly line. They could only process a few drops of liquid at a time. If you had a whole cup of blood, it would take forever.
• The New Way: This platform is like a high-speed conveyor belt. It can process liquid five times faster than before.
  • It combines the sorting (whirlpools) and the shock (electricity) into one seamless workflow.
  • You can now take a messy, real-world sample (like a drop of blood with all kinds of cells mixed in), sort the good ones, zap them with electricity, and deliver the genetic cargo—all in minutes.

4. The "Perfect Recipe" (Optimization)

The scientists didn't just build the machine; they also perfected the "recipe" for the cells.

• They realized that just zapping the cells wasn't enough. The liquid the cells swim in (the buffer) matters.
• They discovered that mixing a specific nutrient soup (Opti-MEM) with a little bit of DMSO (a common lab chemical) acts like a protective coat. It makes the cell walls slightly more flexible, so the electric shock can open them up without breaking them.
• They tested this on two types of "cargo":
  • Plasmid DNA: A large, heavy instruction manual.
  • mRNA: A smaller, faster messenger note.
  • Result: The machine successfully delivered both, even the large, difficult ones, with high success rates.

Why Does This Matter?

Think of this platform as a universal translator for human biology.

• Before, scientists could only easily study "fake" cells (cell lines) that didn't behave like real humans.
• Now, they can take real cells from a patient, quickly and safely insert new genetic instructions, and see how they react.
• This opens the door for personalized medicine. Imagine testing a new cancer drug on your specific cancer cells in a lab before giving it to you, or creating custom cell therapies for rare diseases without the risks of using viruses.

In short: The authors built a machine that acts like a smart, high-speed whirlpool sorter that gently catches specific human cells, gives them a precise electric "nudge" to open the door, and delivers genetic instructions with a success rate that rivals the best chemical methods, but much faster and safer.

Technical Summary

1. Problem Statement

Primary human cells are the gold standard for modeling native human physiology and disease mechanisms but are notoriously difficult to genetically manipulate.

• Limitations of Current Methods:
  • Viral/Chemical Methods: Suffer from cytotoxicity, immunogenicity, potential genome integration, and reliance on complex carrier materials.
  • Conventional Bulk Electroporation: Lacks uniformity for heterogeneous cell samples, requires high voltages that damage cells, and offers poor reproducibility.
  • Existing Microfluidic Systems: While they offer precise control, most focus solely on the transfection step. They often assume pre-purified, homogeneous input samples, lacking the upstream integration of size-selective cell isolation required for real-world, heterogeneous biological samples (e.g., whole blood or tissue digests).
• The Gap: There is a need for a unified workflow that combines size-selective cell trapping, high-throughput processing, and optimized electroporation parameters specifically tailored for fragile, heterogeneous primary cells.

2. Methodology

The authors developed a fully integrated microfluidic platform that combines vortex-based cell trapping with a redesigned electroporation array.

A. Device Design and Fabrication

• Vortex Trapping: Utilizes a commercially validated geometry (based on VTX-1) where cells are hydrodynamically trapped in microscale vortices based on size. This enriches larger primary cells while allowing smaller debris to pass.
• Electrode Array Redesign:
  • Previous Iteration: 4×10 layout (40 chambers).
  • New Iteration: A 12×12 layout (144 chambers) was engineered to increase throughput.
  • Electrical Optimization: To address voltage drops and resistive losses in parallel systems, the team used SPICE circuit modeling to optimize routing. They compared 16×12, 16×9, and 12×12 configurations. The 12×12 configuration was selected because it minimized the required input voltage (24.0 V vs. 39.1 V for the 16×12) while maintaining high voltage efficiency (79.4%) and device stability, preventing electrode erosion.
• Materials: PDMS bonded to a glass slide with a micropatterned gold electrode array.

B. Operational Workflow

1. Sample Loading: Cells enter via an inlet and are trapped in vortices within the chambers.
2. Solution Exchange: A pneumatic system switches the buffer from a wash buffer to an electroporation buffer containing the genetic cargo.
3. Electroporation: Tunable electrical pulses (voltage, frequency, pulse width, count) are applied via the integrated electrode array.
4. Collection: Transfected cells are flushed out to an outlet for downstream analysis.

C. Optimization Strategy

• Cell Models: Immortalized lines (MCF-7, HEK 293) for initial validation; Human Mammary Fibroblasts (HMFs) as the primary cell model.
• Parameter Tuning:
  • Electrical: Voltage, pulse count, frequency, and waveform.
  • Chemical: Buffer composition (DPBS vs. Opti-MEM) and additives (DMSO).
  • Cargo: Plasmid DNA (ZsGreen, hTERT) and in vitro-transcribed (IVT) mRNA (eGFP).
• Variables: Cell passage number (low vs. high passage) and plasmid size (4.7 kb vs. 9.0 kb).

3. Key Contributions

1. Enhanced Throughput Architecture: Successfully scaled the electroporation array from 40 to 144 chambers, achieving a 5-fold increase in processing throughput (5.2 mL/min vs. 1.0 mL/min) while maintaining precise electrical control.
2. Integrated Workflow: Created a unified system that performs size-selective enrichment and transfection in a single device, eliminating the need for pre-purification of heterogeneous samples.
3. Systematic Parameter Optimization: Established a robust protocol for primary cells, identifying that buffer composition (Opti-MEM + DMSO) is as critical as electrical parameters for successful transfection.
4. Multimodal Delivery: Demonstrated compatibility with diverse genetic cargos, including large plasmids (hTERT, 9.0 kb) and mRNA, showing distinct efficiency profiles for each.

4. Key Results

A. Device Performance

• Electrical Efficiency: The 12×12 design reduced the input voltage required to achieve a 900 V/cm field from ~39 V (16×12) to 24 V, significantly improving voltage efficiency (79.4%) and reducing the risk of electrode degradation.
• Throughput: The system processed samples at 5.2 mL/min, a five-fold increase over previous iterations, without compromising the Reynolds number required for stable vortex trapping.
• Trapping: Normalized per-chamber trapping efficiency remained comparable to the previous high-throughput VTX-1 system, confirming that the redesign preserved size-selective capabilities.

B. Primary Cell Transfection (HMFs)

• Buffer Optimization: DPBS alone yielded negligible transfection (<1%). Adding DMSO to DPBS showed minimal improvement. However, switching to Opti-MEM + DMSO resulted in a dramatic, voltage-dependent increase in transfection efficiency.
• Plasmid Delivery:
  • ZsGreen (4.7 kb): Achieved up to 88% of Lipofectamine benchmark efficiency at 16–18 V with 200 µg/mL plasmid.
  • hTERT (9.0 kb): Successfully delivered a large, non-reporter plasmid. Interestingly, high-passage (senescent) cells showed higher transfection efficiency (7.84%) than low-passage cells (4.07%) at 16 V, suggesting senescence alters membrane susceptibility.
• mRNA Delivery:
  • Using N1-methylpseudouridine-modified mRNA with CleanCap AG, the platform achieved 76.2% transfection efficiency (78% of Lipofectamine benchmark).
  • mRNA delivery showed higher efficiency and lower cytotoxicity compared to plasmid DNA, likely due to bypassing nuclear import barriers.

C. Trade-offs

• Viability vs. Efficiency: As expected, higher voltages increased delivery efficiency but decreased cell viability and recovery. An optimal balance was found at 16–18 V, providing high delivery rates while maintaining acceptable cell health.

5. Significance

• Translational Potential: This platform bridges the gap between research-grade microfluidics and clinical applications by handling heterogeneous, real-world samples without extensive pre-processing.
• Scalability: The 5-fold throughput increase makes the technology viable for processing larger sample volumes required for clinical trials or personalized medicine.
• Versatility: The ability to tune both electrical and chemical parameters allows the platform to be adapted for various primary cell types (e.g., T cells, stem cells) and cargo types (CRISPR components, mRNA vaccines).
• Carrier-Free Gene Delivery: It offers a robust, non-viral alternative to viral vectors and chemical reagents, addressing safety concerns regarding immunogenicity and genome integration.

In conclusion, this work presents a scalable, integrated solution for the "holy grail" of primary cell engineering: efficient, high-throughput, and carrier-free genetic delivery that accommodates the heterogeneity and fragility of native human cells.